Psilocybin and MDMA in Australian psychiatry — three years in

What happened

In February 2023, the Therapeutic Goods Administration down-scheduled psilocybin and MDMA from Schedule 9 (prohibited substances) to Schedule 8 (controlled substances) for two specific psychiatric indications:

• Psilocybin — for treatment-resistant depression (adults, after failure of at least two adequate trials of conventional therapy)
• MDMA — for post-traumatic stress disorder (adults, after failure of conventional therapy)

The decision made Australia the first country to formally regulate prescribing of either substance for psychiatric use. Crucially, the pathway is not Schedule 4 (standard prescribing). It runs through the TGA Authorised Prescriber scheme, which restricts prescribing to consultant psychiatrists who have:

• Completed an application demonstrating relevant experience and training
• Received endorsement from a Human Research Ethics Committee
• Obtained TGA approval as an Authorised Prescriber for the specific substance and indication

Three years on, the RANZCP position statement recognises the pathway, while emphasising that the evidence base remains evolving and that delivery must occur within a structured psychotherapy programme.

What it means clinically

Several practical features of the AU rollout matter for general practice.

This is not a take-home medication. Both substances are administered in supervised psychotherapy sessions — typically two preparatory sessions, two to three dosing sessions over several months, and several integration-therapy sessions afterwards. The medication is one element of a structured course; psychotherapy is the other. A patient does not receive a script and a bottle of capsules.

Access is concentrated in private practice. A small number of AU psychiatrists have completed the Authorised Prescriber process, almost exclusively in private metropolitan practice. Public-sector mental-health services are not delivering psilocybin- or MDMA-assisted therapy at any meaningful scale. Wait times where the service is available are reported to be significant.

Cost is substantial. Publicly reported figures sit in the AUD $20,000–$30,000 range for a complete psilocybin course and similar for an MDMA-assisted PTSD course. Neither is PBS-listed; neither is reliably covered by private health insurance under standard mental-health benefits.

Eligibility is narrow. Treatment-resistant depression criteria require documented failure of at least two adequate antidepressant trials in the current episode. PTSD criteria require a diagnosis and history of treatment failure. Active psychosis, current substance dependence, and significant cardiovascular disease are exclusions. A psychiatrist makes the eligibility call, not the GP.

Evidence base is real but small. For MDMA in PTSD, two pivotal trials — MAPP1 (Nat Med 2021) and MAPP2 (Nat Med 2023) — showed clinically meaningful reductions in PTSD severity at 18 weeks compared with placebo plus identical therapy. For psilocybin in TRD, the Goodwin phase-2b trial (NEJM 2022) showed a single 25 mg dose produced rapid antidepressant response superior to a 1 mg active-comparator control, and a smaller head-to-head trial against escitalopram (Carhart-Harris, NEJM 2021) showed comparable outcomes on the primary endpoint with different side-effect profiles.

The complication: in August 2024 the FDA rejected the Lykos (formerly MAPS) MDMA new-drug application, citing concerns over trial methodology, possible expectancy bias from the unblindable nature of MDMA-assisted therapy, allegations around trial integrity, and broader risk-of-bias issues. The AU pathway is unaffected because Authorised Prescriber operates under a different regulatory framework, but the FDA decision has prompted reasonable second looks at the evidence quality.

My take

MAYBE — watch this.

There is a real signal in both indications. Two RCTs hitting the primary endpoint in PTSD is not nothing. A phase-2b psilocybin trial showing rapid response in treatment-resistant depression is not nothing. The mechanism — serotonergic and oxytocinergic neuroplasticity facilitated by a psychotherapy frame — has biological plausibility and animal-model support.

What stops it from being a YES, today, for any patient:

1. Trial numbers are small by the standard of established psychiatric medications. SSRIs were trialled across tens of thousands of patients before becoming routine; MDMA-assisted therapy has been tested in low hundreds.
2. Unblindable interventions raise expectancy bias — patients almost always know whether they received MDMA or placebo. The FDA’s 2024 critique on this point is legitimate.
3. Treatment access is the bottleneck — even if the science were fully settled, the Authorised Prescriber pathway is delivering a small number of treatments per year in private practice at $20,000+ out-of-pocket cost. This is not a population-scale intervention in 2026.
4. Integration into routine care is unresolved — no clear answer yet on long-term durability of response, retreatment intervals, or how it fits alongside existing antidepressants and SSRI-tapering decisions.

What would shift the call to YES:

• Phase-3 psilocybin trials (COMP005 / COMP006) reading out cleanly with effect sizes consistent with the phase-2b signal
• PBS listing or state-funded delivery model bringing cost into a normal mental-health-treatment range
• Public-sector availability through state mental-health services rather than only private psychiatry
• Two-year durability data showing sustained response, not just acute remission

What to do now (for clinicians and patients):

• Patient with treatment-resistant depression asking about psilocybin? Discuss the realistic pathway: documentation of TRD criteria, referral to a psychiatrist with Authorised Prescriber approval if patient and GP both want to pursue it, honest conversation about cost and evidence uncertainty, and continued optimisation of conventional care in parallel.
• Patient with PTSD asking about MDMA-assisted therapy? Similar honest pathway: PTSD diagnosis confirmed, conventional therapy (trauma-focused CBT, EMDR, sertraline or venlafaxine) trialled adequately, Authorised Prescriber referral as a private option, awareness of the FDA decision and what it does and doesn’t change.
• Patient curious but stable on conventional treatment? Probably not the right time to switch. The AU pathway is for treatment-resistant illness, not first-line care.

This is one of those areas where the marketing has run ahead of the trial evidence, and the trial evidence has run ahead of the access pathway. All three need to align before this becomes routine medicine.

What this is and is not

This is general health information based on Australian regulatory decisions and the published trial evidence. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about whether psilocybin- or MDMA-assisted therapy is appropriate are made with a treating psychiatrist who can assess eligibility against the Authorised Prescriber criteria.

If you are experiencing a mental-health crisis or thoughts of suicide or self-harm, call Lifeline on 13 11 14 or attend an emergency department. For non-urgent treatment-resistant depression or PTSD, the first step is a long consultation with your GP and a referral pathway into psychiatry.

---

Sources cited

1. TGA — Change to the classification of psilocybin and MDMA (Feb 2023)
2. TGA — Authorised Prescriber scheme overview
3. RANZCP — Clinical guidelines and position statements
4. Australian Prescriber
5. MAPP1 — Mitchell et al., Nat Med 2021
6. MAPP2 — Mitchell et al., Nat Med 2023
7. Goodwin et al. — Psilocybin in TRD (NEJM 2022)
8. Carhart-Harris et al. — Psilocybin vs escitalopram (NEJM 2021)
9. FDA — Lykos (MAPS) decision archive
10. PBS Australia
11. Beyond Blue, Lifeline